Symbols / CMND
CMND Chart
About
Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, the company has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; Yissum Research Development Company of the Hebrew University of Jerusalem to develop, manufacture, and commercialize compounds targeted at treating post-traumatic stress disorder and other health conditions; and Polyrizon Ltd. to develop novel intranasal MEAI formulation. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.74M |
| Enterprise Value | -3.62M | Income | -3.86M | Sales | — |
| Book/sh | 7.54 | Cash/sh | 35.33 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | 0.15 | P/C | — |
| EV/EBITDA | 0.64 | EV/Sales | — | Quick Ratio | 1.21 |
| Current Ratio | 1.22 | Debt/Eq | 149.16 | LT Debt/Eq | — |
| EPS (ttm) | -30.35 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | — | ROA | -53.11% |
| ROE | -179.39% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 1.50M |
| Shs Float | 123.25K | Short Float | 1.96% | Short Ratio | 0.24 |
| Short Interest | — | 52W High | 53.72 | 52W Low | 1.05 |
| Beta | -1.12 | Avg Volume | 370.25K | Volume | 23.56K |
| Target Price | — | Recom | None | Prev Close | $1.15 |
| Price | $1.16 | Change | 0.87% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$1.16
Latest analyst target
3. DCF / Fair value
$-45.84
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.16
Low
—
High
—
Mean
—
- Clearmind Medicine Inc. Announces 1-for-40 Reverse Share Split to Regain Nasdaq Compliance - Quiver Quantitative Wed, 10 Dec 2025 08
- Clearmind Medicine stock rises after positive safety data in alcohol disorder trial - Investing.com Mon, 24 Nov 2025 08
- Why Is Clearmind Stock Down Today? - Sahm Fri, 07 Nov 2025 08
- Clearmind Medicine To Implement 1-for-40 Reverse Stock Split Next Week - Nasdaq hu, 11 Dec 2025 08
- Clearmind Medicine (CMND) Stock Soars Thursday: What's Going On? - Benzinga hu, 13 Nov 2025 08
- What is CMND’s book value per share - Gap Down & Low Risk Entry Point Guides - mfd.ru Sat, 21 Feb 2026 03
- CMND’s Market Pulse: A Look Ahead - StocksToTrade Fri, 19 Sep 2025 07
- Clearmind Medicine Inc. Reports Positive Safety Results from Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder - Quiver Quantitative Mon, 09 Feb 2026 08
- Clearmind Medicine stock falls after Phase I/IIa trial safety update - Investing.com Mon, 09 Feb 2026 08
- Clearmind Medicine Announces Additional Positive Safety Topline Data From CMND-100 Study - Nasdaq Mon, 09 Feb 2026 08
- Clearmind Medicine Inc. Advances CMND-100 Clinical Trial for Alcohol Use Disorder Treatment Targeting $20 Billion Market | CMND Stock News - Quiver Quantitative Mon, 10 Nov 2025 08
- Clearmind Medicine stock drops after Nasdaq compliance notice - Investing.com Fri, 05 Dec 2025 08
- Clearmind Medicine Inc. Expands Phase I/IIa Clinical Trial for CMND-100 with Tel Aviv Sourasky Medical Center Collaboration - Nasdaq Mon, 23 Jun 2025 07
- Clearmind Medicine Inc. Regains Compliance with Nasdaq Listing Rule on Minimum Stockholders’ Equity - Quiver Quantitative Fri, 12 Dec 2025 08
- Clearmind Medicine receives Nasdaq non-compliance notice over equity rule - Investing.com hu, 06 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 109167 | 11790 | — | Stock split or consolidation at price 0.11 per share. | Rootenberg (Alan) | Director of Issuer | — | 2025-05-13 00:00:00 | D |
| 1 | 13454 | 79849 | — | Stock split or consolidation at price 5.94 per share. | Rootenberg (Alan) | Director of Issuer | — | 2025-05-13 00:00:00 | D |
| 2 | 9461 | 9461 | — | Exercise of rights at price 1.00 per share. | Rootenberg (Alan) | Director of Issuer | — | 2025-05-13 00:00:00 | D |
| 3 | 5827 | 5827 | — | Exercise of rights at price 1.00 per share. | Rootenberg (Alan) | Director of Issuer | — | 2025-05-13 00:00:00 | D |
Financials
| Line Item | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 296.47K | 94.97K | -943.68K | -157.04K |
| TaxRateForCalcs | 0.15 | 0.15 | 0.40 | 0.26 |
| NormalizedEBITDA | -5.69M | -5.42M | -6.18M | -6.17M |
| TotalUnusualItems | 1.98M | 633.15K | -2.36M | -599.16K |
| TotalUnusualItemsExcludingGoodwill | 1.98M | 633.15K | -2.36M | -599.16K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -3.86M | -5.25M | -8.62M | -6.89M |
| ReconciledDepreciation | 49.37K | 51.07K | 57.51K | 83.07K |
| EBITDA | -3.72M | -4.79M | -8.54M | -6.77M |
| EBIT | -3.77M | -4.84M | -8.59M | -6.85M |
| NetInterestIncome | 113.37K | 235.06K | 59.17K | -14.42K |
| InterestExpense | 19.54K | 36.16K | 10.89K | 14.42K |
| InterestIncome | 132.91K | 271.22K | 70.07K | 0.00 |
| NormalizedIncome | -5.54M | -5.79M | -7.21M | -6.45M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -3.86M | -5.25M | -8.62M | -6.89M |
| TotalExpenses | 5.67M | 5.74M | 6.30M | 6.25M |
| DilutedAverageShares | 77.50K | 5.06K | 1.08K | 1.04K |
| BasicAverageShares | 77.50K | 5.06K | 1.08K | 1.04K |
| DilutedEPS | -67.80 | -1.70K | -6.38K | -2.62K |
| BasicEPS | -67.80 | -1.70K | -6.38K | -2.62K |
| DilutedNIAvailtoComStockholders | -3.86M | -5.25M | -8.62M | -6.89M |
| NetIncomeCommonStockholders | -3.86M | -5.25M | -8.62M | -6.89M |
| NetIncome | -3.86M | -5.25M | -8.62M | -6.89M |
| NetIncomeIncludingNoncontrollingInterests | -3.86M | -5.25M | -8.62M | -6.89M |
| NetIncomeContinuousOperations | -3.86M | -5.25M | -8.62M | -6.89M |
| TaxProvision | 70.44K | 377.97K | 17.37K | 29.86K |
| PretaxIncome | -3.79M | -4.88M | -8.60M | -6.87M |
| OtherIncomeExpense | 1.77M | 633.15K | -2.36M | -599.16K |
| OtherNonOperatingIncomeExpenses | -209.20K | |||
| SpecialIncomeCharges | 0.00 | 0.00 | -7.33K | |
| ImpairmentOfCapitalAssets | 0.00 | 0.00 | 7.33K | |
| GainOnSaleOfSecurity | 1.98M | 633.15K | -2.36M | -599.16K |
| NetNonOperatingInterestIncomeExpense | 113.37K | 235.06K | 59.17K | -14.42K |
| TotalOtherFinanceCost | -59.17K | 10.59K | ||
| InterestExpenseNonOperating | 19.54K | 36.16K | 10.89K | 14.42K |
| InterestIncomeNonOperating | 132.91K | 271.22K | 70.07K | 0.00 |
| OperatingIncome | -5.67M | -5.74M | -6.30M | -6.25M |
| OperatingExpense | 5.67M | 5.74M | 6.30M | 6.25M |
| DepreciationAmortizationDepletionIncomeStatement | 38.41K | 40.09K | 37.30K | 68.24K |
| DepreciationAndAmortizationInIncomeStatement | 38.41K | 40.09K | 37.30K | 68.24K |
| DepreciationIncomeStatement | 38.41K | 40.09K | 37.30K | 68.24K |
| ResearchAndDevelopment | 2.06M | 1.38M | 1.54M | 3.08M |
| SellingGeneralAndAdministration | 3.57M | 4.32M | 4.72M | 3.10M |
| GeneralAndAdministrativeExpense | 3.57M | 4.32M | 4.72M | 3.10M |
| OtherGandA | 2.51M | 2.82M | 4.08M | 1.91M |
| InsuranceAndClaims | 268.74K | 329.28K | 364.06K | 149.54K |
| SalariesAndWages | 790.28K | 1.18M | 281.56K | 1.04M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 158.08K | 106.63K | 15.18K | 1.10K |
| ShareIssued | 158.08K | 106.63K | 15.18K | 1.10K |
| TotalDebt | 1.78M | 53.14K | 0.00 | 38.39K |
| TangibleBookValue | 1.10M | 3.00M | 864.16K | -1.24M |
| InvestedCapital | 2.95M | 3.11M | 983.47K | -1.11M |
| WorkingCapital | 1.06M | 2.96M | 824.76K | -1.50M |
| NetTangibleAssets | 1.10M | 3.00M | 864.16K | -1.24M |
| CapitalLeaseObligations | 18.80K | 53.14K | 0.00 | 38.39K |
| CommonStockEquity | 1.19M | 3.11M | 983.47K | -1.11M |
| TotalCapitalization | 1.19M | 3.11M | 983.47K | -1.11M |
| TotalEquityGrossMinorityInterest | 1.19M | 3.11M | 983.47K | -1.11M |
| StockholdersEquity | 1.19M | 3.11M | 983.47K | -1.11M |
| OtherEquityInterest | 2.69M | 2.98M | 2.64M | 2.36M |
| GainsLossesNotAffectingRetainedEarnings | -21.25K | -21.25K | -21.25K | -21.25K |
| OtherEquityAdjustments | -21.25K | -21.25K | -21.25K | -21.25K |
| RetainedEarnings | -27.88M | -24.02M | -18.77M | -10.15M |
| CapitalStock | 26.40M | 24.17M | 17.13M | 6.71M |
| CommonStock | 26.40M | 24.17M | 17.13M | 6.71M |
| TotalLiabilitiesNetMinorityInterest | 4.89M | 4.15M | 4.97M | 1.93M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 16.42K | 0.00 | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 16.42K | 0.00 | |
| LongTermCapitalLeaseObligation | 0.00 | 16.42K | 0.00 | |
| CurrentLiabilities | 4.89M | 4.13M | 4.97M | 1.93M |
| OtherCurrentLiabilities | 2.37M | 3.52M | 4.31M | 290.57K |
| CurrentDebtAndCapitalLeaseObligation | 1.78M | 36.73K | 38.39K | |
| CurrentCapitalLeaseObligation | 18.80K | 36.73K | 0.00 | 38.39K |
| CurrentDebt | 1.76M | |||
| OtherCurrentBorrowings | 1.76M | |||
| PayablesAndAccruedExpenses | 742.39K | 575.02K | 659.44K | 1.60M |
| Payables | 742.39K | 575.02K | 659.44K | 1.60M |
| DuetoRelatedPartiesCurrent | 60.23K | 48.96K | 42.43K | 206.49K |
| AccountsPayable | 682.16K | 526.06K | 617.00K | 1.40M |
| TotalAssets | 6.08M | 7.26M | 5.95M | 826.41K |
| TotalNonCurrentAssets | 135.33K | 167.18K | 158.71K | 391.72K |
| OtherNonCurrentAssets | 20.56K | 7.19K | 37.67K | 14.65K |
| NonCurrentDeferredAssets | 0.00 | 198.17K | 0.00 | |
| GoodwillAndOtherIntangibleAssets | 97.37K | 108.33K | 119.31K | 130.26K |
| OtherIntangibleAssets | 177.80K | 159.80K | ||
| NetPPE | 17.40K | 51.66K | 1.73K | 48.63K |
| AccumulatedDepreciation | -25.58K | -13.19K | ||
| GrossPPE | 17.40K | 51.66K | 1.73K | 48.63K |
| OtherProperties | 1.73K | 12.90K | 16.60K | |
| BuildingsAndImprovements | 17.40K | 51.66K | 0.00 | 35.73K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 5.95M | 7.09M | 5.79M | 434.69K |
| PrepaidAssets | 39.94K | 44.16K | 40.40K | 14.24K |
| Receivables | 322.31K | 180.88K | 240.32K | 97.92K |
| OtherReceivables | 35.83K | 49.04K | 104.32K | 50.93K |
| DuefromRelatedPartiesCurrent | 286.49K | 131.84K | 136.00K | 46.99K |
| AccountsReceivable | 160.87K | |||
| CashCashEquivalentsAndShortTermInvestments | 5.59M | 6.86M | 5.51M | 322.53K |
| OtherShortTermInvestments | 1.66M | 289.39K | 86.11K | 193.75K |
| CashAndCashEquivalents | 3.92M | 6.57M | 5.43M | 128.78K |
| CashFinancial | 175.77K | 3.71M |
| Line Item | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| FreeCashFlow | -4.73M | -4.86M | -6.30M | -3.73M |
| RepaymentOfDebt | -42.54K | -42.59K | -40.92K | -70.87K |
| IssuanceOfDebt | 2.25M | 0.00 | 0.00 | |
| IssuanceOfCapitalStock | 0.00 | 2.19M | 11.12M | 582.56K |
| CapitalExpenditure | -5.56K | -169.38K | ||
| InterestPaidSupplementalData | 3.86K | 5.39K | 2.91K | 14.43K |
| IncomeTaxPaidSupplementalData | 229.91K | 306.59K | 12.68K | 0.00 |
| EndCashPosition | 3.92M | 6.57M | 5.43M | 128.78K |
| BeginningCashPosition | 6.57M | 5.43M | 128.78K | 3.37M |
| EffectOfExchangeRateChanges | 3.22K | -11.55K | -37.73K | -22.65K |
| ChangesInCash | -2.65M | 1.16M | 5.34M | -3.22M |
| FinancingCashFlow | 2.62M | 6.25M | 11.66M | 511.69K |
| CashFlowFromContinuingFinancingActivities | 2.62M | 6.25M | 11.66M | 511.69K |
| NetOtherFinancingCharges | -600.49K | |||
| InterestPaidCFF | -14.47K | 0.00 | ||
| ProceedsFromStockOptionExercised | 415.09K | 4.10M | 590.08K | 0.00 |
| CashDividendsPaid | 0.00 | 0.00 | ||
| NetCommonStockIssuance | 0.00 | 2.19M | 11.12M | 582.56K |
| CommonStockIssuance | 0.00 | 2.19M | 11.12M | 582.56K |
| NetIssuancePaymentsOfDebt | 2.21M | -42.59K | -40.92K | -70.87K |
| NetLongTermDebtIssuance | 2.21M | -42.59K | -40.92K | -70.87K |
| LongTermDebtPayments | -42.54K | -42.59K | -40.92K | -70.87K |
| LongTermDebtIssuance | 2.25M | 0.00 | 0.00 | |
| InvestingCashFlow | -542.02K | -238.10K | -26.23K | -5.56K |
| CashFlowFromContinuingInvestingActivities | -542.02K | -238.10K | -26.23K | -5.56K |
| NetOtherInvestingChanges | -13.50K | 33.80K | -26.23K | -14.65K |
| NetInvestmentPurchaseAndSale | -528.52K | -271.90K | 0.00 | 0.00 |
| SaleOfInvestment | 186.07K | 78.50K | 0.00 | 0.00 |
| PurchaseOfInvestment | -714.59K | -350.40K | 0.00 | 0.00 |
| NetIntangiblesPurchaseAndSale | 0.00 | 0.00 | -145.09K | |
| PurchaseOfIntangibles | 0.00 | 0.00 | -145.09K | |
| NetPPEPurchaseAndSale | 0.00 | 0.00 | -5.56K | -24.29K |
| PurchaseOfPPE | 0.00 | 0.00 | -5.56K | -24.29K |
| OperatingCashFlow | -4.73M | -4.86M | -6.30M | -3.72M |
| CashFlowFromContinuingOperatingActivities | -4.73M | -4.86M | -6.30M | -3.72M |
| ChangeInWorkingCapital | -39.57K | -130.11K | -969.03K | 1.24M |
| ChangeInOtherWorkingCapital | -144.05K | 7.22K | -167.86K | 200.44K |
| ChangeInPayablesAndAccruedExpense | 82.79K | -198.59K | -620.42K | 913.30K |
| ChangeInPayable | -788.28K | 1.12M | 251.88K | |
| ChangeInAccountPayable | -620.42K | 915.97K | 251.74K | |
| ChangeInPrepaidAssets | 4.44K | -3.69K | -26.13K | 103.03K |
| ChangeInReceivables | 17.25K | 64.95K | -154.62K | 19.94K |
| OtherNonCashItems | 213.05K | 5.39K | 2.91K | 14.43K |
| StockBasedCompensation | 805.89K | 998.92K | 834.81K | 1.21M |
| UnrealizedGainLossOnInvestmentSecurities | -844.50K | 68.62K | 107.64K | 308.19K |
| AssetImpairmentCharge | 0.00 | 0.00 | 7.33K | |
| DeferredTax | 70.44K | 103.88K | 17.37K | 29.86K |
| DeferredIncomeTax | 70.44K | 103.88K | 17.37K | 29.86K |
| DepreciationAmortizationDepletion | 49.37K | 51.07K | 57.51K | 83.07K |
| DepreciationAndAmortization | 49.37K | 51.07K | 57.51K | 83.07K |
| AmortizationCashFlow | 10.95K | 10.98K | 10.95K | 14.83K |
| AmortizationOfIntangibles | 10.95K | 10.98K | 10.95K | 14.83K |
| Depreciation | 38.41K | 40.09K | 46.56K | 68.24K |
| OperatingGainsLosses | -1.13M | -701.75K | 2.27M | 290.57K |
| GainLossOnInvestmentSecurities | -1.13M | -707.80K | 2.19M | 290.57K |
| NetForeignCurrencyExchangeGainLoss | -3.61K | 6.05K | 78.17K | 0.00 |
| NetIncomeFromContinuingOperations | -3.86M | -5.25M | -8.62M | -6.89M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for CMND
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|